Src kinase inhibitor compounds

US6498165B1 · kind B1 · utility

Assignee

• MERCK & CO., INC. · US

Inventors

• Helen M. Armstrong · Westfield, US
• Richard Thomas Beresis · Shanghai, CN
• Joung Goulet · Westfield, US
• Mark A. Holmes · Middlesex, US
• Xingfang Hong · Westfield, US
• Sander G. Mills · Scotch Plains, US
• William H. Parsons · Montgomery, US
• Peter J. Sinclair · Highland Park, US
• Mark G. Steiner · East Brunswick Township, US
• Frederick Wong · Glen Ridge, US
• Dennis Zaller · Scotch Plains, US

Key dates

• Filing date: Jun 26, 2000
• Grant date: Dec 24, 2002
• Expiry date: Jun 26, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.